Race Oncology Ltd
ASX:RAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
KULR Technology Group Inc
AMEX:KULR
|
US |
Race Oncology Ltd
Other Items
Race Oncology Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Race Oncology Ltd
ASX:RAC
|
Other Items
AU$500
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Items
-$58k
|
CAGR 3-Years
23%
|
CAGR 5-Years
44%
|
CAGR 10-Years
4%
|
|
|
CSL Ltd
ASX:CSL
|
Other Items
-$15m
|
CAGR 3-Years
89%
|
CAGR 5-Years
5%
|
CAGR 10-Years
25%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Other Items
-AU$18.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Items
-AU$229.9m
|
CAGR 3-Years
-384%
|
CAGR 5-Years
-213%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Race Oncology Ltd
Glance View
Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.
See Also
What is Race Oncology Ltd's Other Items?
Other Items
500
AUD
Based on the financial report for Dec 31, 2025, Race Oncology Ltd's Other Items amounts to 500 AUD.
